{Reference Type}: Journal Article
{Title}: [Expert Consensus on the Treatment of Antiangiogenic Agents for Radiation Brain Necrosis].
{Author}: Chen Y;Wang X;Sun B;Meng M;Wang E;Yuan Z;Zhuang H; ;
{Journal}: Zhongguo Fei Ai Za Zhi
{Volume}: 25
{Issue}: 5
{Year}: May 2022 20
暂无{DOI}: 10.3779/j.issn.1009-3419.2022.101.18
{Abstract}: Vascular damage is followed by vascular endothelial growth factor (VEGF) expression at high levels, which is an important mechanism for cerebral radiation necrosis (CRN) development. Antiangiogenic agents (Bevacizumab) alleviates brain edema symptoms caused by CRN through inhibiting VEGF and acting on vascular tissue around the brain necrosis area. Many studies have confirmed that Bevacizumab effectively relieves symptoms caused by brain necrosis, improves patients' performance status and brain necrosis imaging. Considering that the efficacy of antiangiogenic therapy is mainly related to the duration of drug action, low-dose antiangiogenic agents can achieve favorable efficacy. Prevention is the best treatment. The occurrence of CRN is associated with tumor-related factors and treatment-related factors. By controlling these factors, CRN can be effectively prevented.
.<BR>【中文题目：抗血管药物治疗放射性脑坏死专家共识】 【中文摘要：血管内皮生长因子（vascular endothelial growth factor, VEGF）的高水平表达是放射性脑坏死（cerebral radiation necrosis, CRN）发生的重要机制。抗血管生成药物（贝伐珠单抗）通过抑制VEGF，作用于脑坏死区域周围的血管组织，减轻CRN引起的脑水肿。许多研究证实贝伐珠单抗可有效缓解脑坏死症状，改善患者的体力状况评分以及减轻影像学上脑水肿范围。抗血管治疗的疗效主要与药物作用时长相关，低剂量抗血管药物即可达到较好的治疗效果。预防是最好的治疗，CRN的发生与肿瘤相关因素和治疗相关因素相关，通过控制两方面因素，可有效预防CRN。
】 【中文关键词：放射性脑坏死；抗血管生成药物；贝伐珠单抗；专家共识】.